Background
Latozinemab (AL001) is a recombinant human anti-Sortilin monoclonal antibody. Latozinemab effectively binds Sortilin with a high affinity and blocks the interaction between progranulin protein (PGRN) and Sortilin receptor. Latozinemab has the potential for progranulin gene (GRN) mutations causative of Frontotemporal dementia (FTD) (FTD-GRN) research.• The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor., PMID:9756851• Sortilin is dispensable for secondary injury processes following traumatic brain injury in mice., PMID:39170542• Neurotrophins and their involvement in digestive cancers., PMID:30741921• Sortilin Modulates Schwann Cell Signaling and Remak Bundle Regeneration Following Nerve Injury., PMID:35634462• Peptides other than the neurotrophins that can be cleaved from proneurotrophins: a neglected story., PMID:17917853• The Neurotrophin Receptor TrkC as a Novel Molecular Target of the Antineuroblastoma Action of Valproic Acid., PMID:34360553• Proneurotrophin-3 may induce Sortilin-dependent death in inner ear neurons., PMID:21261755• Neurotrophins and their receptors in early development of the mammalian nervous system., PMID:21196952• Proneurotrophin-3 is a neuronal apoptotic ligand: evidence for retrograde-directed cell killing., PMID:19940174